Unknown

Dataset Information

0

Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.


ABSTRACT: As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.

SUBMITTER: van Breemen RB 

PROVIDER: S-EPMC8768006 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9709744 | biostudies-literature
| S-EPMC8610590 | biostudies-literature
| S-EPMC9603820 | biostudies-literature
| S-EPMC8437313 | biostudies-literature
| S-EPMC8848511 | biostudies-literature
| S-EPMC9595563 | biostudies-literature
| S-EPMC7986999 | biostudies-literature
| S-EPMC8606318 | biostudies-literature
| S-EPMC9338828 | biostudies-literature
| S-EPMC8502962 | biostudies-literature